Live Breaking News & Updates on Receiving Breakthrough Designation

Stay updated with breaking news from Receiving breakthrough designation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Timber Pharmaceuticals Provides Business Update and

Timber Enrolls First Patients in Phase 3 ASCEND Clinical Trial after Receiving Breakthrough Designation from FDA for Lead Asset TMB-001 BASKING. ....

United States , Adam Daley , John Koconis , Exchange Commission On , Company Quarterly Form , Drug Administration , Exchange Commission , Company Annual Report On Form , Berry Company Public Relations , Securities Exchange , Products Clinical Trials Grants Program , Timber Pharmaceuticals Inc , Journal Of The American Academy Dermatology , Timber Enrolls First Patients , Receiving Breakthrough Designation , Lead Asset , Timber Pharmaceuticals , Chief Executive Officer , Breakthrough Therapy , Fast Track , Congenital Ichthyosis , Breakthrough Therapy Designation , American Academy , Quarterly Form , Securities Act , Securities Exchange Act ,

Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2022 Financial Results

Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2022 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , John Koconis , Exchange Commission On , Company Quarterly Form , Drug Administration , Timber Pharmaceuticals , Patagonia Pharmaceuticals , Exchange Commission , Company Annual Report On Form , Adam Daleyberry Company Public Relations , Securities Exchange , Timber Pharmaceuticals Inc , Products Clinical Trials Grants Program , Timber Pharmaceuticals Inc John Koconischairman , Journal Of The American Academy Dermatology , Wall Street , Enrolls First Patients , Receiving Breakthrough Designation , Lead Asset , Chief Executive Officer , Breakthrough Therapy , Fast Track , Congenital Ichthyosis , Breakthrough Therapy Designation , American Academy , Quarterly Form ,

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

United States , Adam Daley , John Koconis , Exchange Commission On , Company Quarterly Form , Drug Administration , Patagonia Pharmaceuticals , Exchange Commission , Company Annual Report On Form , Berry Company Public Relations , Securities Exchange , Timber Pharmaceuticals Inc , Products Clinical Trials Grants Program , Journal Of The American Academy Dermatology , Timber Enrolls First Patients , Receiving Breakthrough Designation , Lead Asset , Chief Executive Officer , Breakthrough Therapy , Fast Track , Congenital Ichthyosis , Breakthrough Therapy Designation , American Academy , Quarterly Form , Timber Pharmaceuticals , Securities Act ,

CASI Pharmaceuticals Announces CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy Designation

Share this article
Share this article
ROCKVILLE, Md., and BEIJING, Dec. 23, 2020 /PRNewswire/ CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that the Chinese Center for Drug Evaluation, a division of the China National Medical Products Association, has granted Breakthrough Therapy Designation ( Breakthrough Designation ) to its partner Juventas Cell Therapy Ltd. for CNCT19, a potential CD19 CAR-T therapy for the treatment of adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). CASI has co-commercial rights to CNCT19 and is a shareholder of Juventas.
The Breakthrough Designation for CNCT19 was granted based on initial data from the ongoing single arm, open-label, non-randomized, dose-escalation, Phase I study designed to determine the safety and efficacy of CNCT19 in B-ALL. ....

United States , Jennifer Porcelli , Institute Of Hematology , Chinese Center , China National Medical Products Association , Pharmaceuticals China Co Ltd , Juventas Cell Therapy Ltd , Pharmaceuticals Inc , Chinese Academy Of Medical Sciences , Drug Evaluation , Breakthrough Therapy Designation , Juventas Cell Therapy , Breakthrough Designation , Drug Registration Regulation , Receiving Breakthrough Designation , Cell Therapy , Tianjin City , Chinese Academy , Medical Sciences , Private Securities Litigation Reform Act , ஒன்றுபட்டது மாநிலங்களில் , ஜெனிபர் போர்செல்லி , நிறுவனம் ஆஃப் ஹீமாட்டாலஜி , சீன மையம் , சீனா தேசிய மருத்துவ ப்ராடக்ட்ஸ் சங்கம் , மருந்துகள் சீனா இணை லிமிடெட் ,